SE453497B - Antitumormedel och kompositioner pa basis derav samt forfarande for framstellning av dessa kompositioner - Google Patents
Antitumormedel och kompositioner pa basis derav samt forfarande for framstellning av dessa kompositionerInfo
- Publication number
- SE453497B SE453497B SE8100341A SE8100341A SE453497B SE 453497 B SE453497 B SE 453497B SE 8100341 A SE8100341 A SE 8100341A SE 8100341 A SE8100341 A SE 8100341A SE 453497 B SE453497 B SE 453497B
- Authority
- SE
- Sweden
- Prior art keywords
- amsa
- solution
- organic acid
- gluconolactone
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 42
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000002246 antineoplastic agent Substances 0.000 title 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 57
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 49
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 29
- 235000012208 gluconic acid Nutrition 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000174 gluconic acid Substances 0.000 claims description 27
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 26
- 229960003681 gluconolactone Drugs 0.000 claims description 26
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 25
- 150000007524 organic acids Chemical class 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 18
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 2
- -1 9-acridinylamino Chemical group 0.000 claims 1
- XXNAQBNJPZNRSZ-UHFFFAOYSA-N n-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide;2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OCC(O)C(O)C(O)C(O)C(O)=O.COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XXNAQBNJPZNRSZ-UHFFFAOYSA-N 0.000 claims 1
- 229950006191 gluconic acid Drugs 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 18
- 230000003287 optical effect Effects 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000006207 intravenous dosage form Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11480980A | 1980-01-24 | 1980-01-24 | |
| US06/194,350 US4322424A (en) | 1980-01-24 | 1980-10-17 | Crystalline glucoconate salt of m-AMSA and compositions containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8100341L SE8100341L (sv) | 1981-07-25 |
| SE453497B true SE453497B (sv) | 1988-02-08 |
Family
ID=26812557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8100341A SE453497B (sv) | 1980-01-24 | 1981-01-21 | Antitumormedel och kompositioner pa basis derav samt forfarande for framstellning av dessa kompositioner |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4322424A (en, 2012) |
| AT (1) | AT380474B (en, 2012) |
| AU (1) | AU543758B2 (en, 2012) |
| CA (1) | CA1252103A (en, 2012) |
| CH (1) | CH648023A5 (en, 2012) |
| DE (1) | DE3102026A1 (en, 2012) |
| DK (1) | DK29781A (en, 2012) |
| FI (1) | FI79840C (en, 2012) |
| FR (1) | FR2474493B1 (en, 2012) |
| GB (1) | GB2068729B (en, 2012) |
| GR (1) | GR82326B (en, 2012) |
| IE (1) | IE50884B1 (en, 2012) |
| IT (1) | IT1170638B (en, 2012) |
| LU (1) | LU83081A1 (en, 2012) |
| NL (1) | NL8100292A (en, 2012) |
| SE (1) | SE453497B (en, 2012) |
| YU (1) | YU42552B (en, 2012) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU186383B (en) * | 1981-02-27 | 1985-07-29 | Biogal Gyogyszergyar | Process for producing new citostatic amni-acridie-alpha, beta-bracket-d-bracket closed, or aracket-l-bracket closed-n-glycoside derivatives and salts |
| US4575509A (en) * | 1983-01-31 | 1986-03-11 | Bristol-Myers Company | Water-soluble formulations of m-AMSA with pyroglutamic acid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1674923A (en) * | 1924-04-12 | 1928-06-26 | Schnorf Carl | Process for the production of carbohydrate-acridine compounds and solutions thereof |
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| US4258191A (en) * | 1979-03-29 | 1981-03-24 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Multi-step process for the production of methanesulfon-m-anisidide, 4'-(9-acridinylamino)- |
| AU534608B2 (en) * | 1979-09-14 | 1984-02-09 | Warner-Lambert Corporation | Compounds having antitumour properties |
| ZA811304B (en) * | 1980-03-11 | 1982-06-30 | Warner Lambert Co | Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide |
-
1980
- 1980-10-17 US US06/194,350 patent/US4322424A/en not_active Expired - Lifetime
-
1981
- 1981-01-20 YU YU145/81A patent/YU42552B/xx unknown
- 1981-01-21 SE SE8100341A patent/SE453497B/sv not_active IP Right Cessation
- 1981-01-21 IT IT47604/81A patent/IT1170638B/it active
- 1981-01-21 NL NL8100292A patent/NL8100292A/nl not_active Application Discontinuation
- 1981-01-21 AU AU66512/81A patent/AU543758B2/en not_active Ceased
- 1981-01-22 CA CA000369109A patent/CA1252103A/en not_active Expired
- 1981-01-22 DK DK29781A patent/DK29781A/da not_active Application Discontinuation
- 1981-01-22 DE DE19813102026 patent/DE3102026A1/de active Granted
- 1981-01-22 FI FI810180A patent/FI79840C/fi not_active IP Right Cessation
- 1981-01-23 GB GB8102175A patent/GB2068729B/en not_active Expired
- 1981-01-23 GR GR63955A patent/GR82326B/el unknown
- 1981-01-23 IE IE119/81A patent/IE50884B1/en unknown
- 1981-01-23 LU LU83081A patent/LU83081A1/fr unknown
- 1981-01-23 FR FR8101233A patent/FR2474493B1/fr not_active Expired
- 1981-01-26 AT AT0032681A patent/AT380474B/de not_active IP Right Cessation
- 1981-01-26 CH CH484/81A patent/CH648023A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3102026A1 (de) | 1982-03-04 |
| GB2068729A (en) | 1981-08-19 |
| AU543758B2 (en) | 1985-05-02 |
| FI79840C (fi) | 1990-03-12 |
| CA1252103A (en) | 1989-04-04 |
| DE3102026C2 (en, 2012) | 1990-05-31 |
| IE810119L (en) | 1981-07-24 |
| AU6651281A (en) | 1981-07-30 |
| YU42552B (en) | 1988-10-31 |
| DK29781A (da) | 1981-07-25 |
| FR2474493B1 (fr) | 1985-12-13 |
| CH648023A5 (de) | 1985-02-28 |
| NL8100292A (nl) | 1981-08-17 |
| GB2068729B (en) | 1983-10-19 |
| IT8147604A0 (it) | 1981-01-21 |
| AT380474B (de) | 1986-05-26 |
| GR82326B (en, 2012) | 1984-12-13 |
| FI79840B (fi) | 1989-11-30 |
| US4322424A (en) | 1982-03-30 |
| FR2474493A1 (fr) | 1981-07-31 |
| FI810180L (fi) | 1981-07-25 |
| IT1170638B (it) | 1987-06-03 |
| SE8100341L (sv) | 1981-07-25 |
| ATA32681A (de) | 1985-10-15 |
| LU83081A1 (fr) | 1981-09-10 |
| IE50884B1 (en) | 1986-08-06 |
| YU14581A (en) | 1983-06-30 |
| IT8147604A1 (it) | 1982-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2568401B2 (ja) | 水溶性メグルミン塩及びグルカミン塩、その製造方法並びにこれを含有する医薬組成物 | |
| TW200944508A (en) | Novel solid forms of bendamustine hydrochloride | |
| ES2870614T3 (es) | Hemihidrato de la base libre de la N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, métodos para su fabricación y sus usos | |
| KR880002087B1 (ko) | 항균성 나프티리딘 또는 퀴놀린 화합물의 염 및 그의 제조방법 | |
| KR20070026187A (ko) | 2개 이상의 활성 물질을 함유하는 주사용 멸균 약제학적제형 | |
| KR20250090265A (ko) | 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 | |
| JPS6145626B2 (en, 2012) | ||
| JPH0248526A (ja) | インドメタシン注射剤およびその製造方法 | |
| PT91132B (pt) | Processo para a preparacao de hidrohaletos de rifapentina | |
| HRP20020231A2 (en) | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A | |
| CA1160571A (en) | Antitumor compositions | |
| US4772589A (en) | Etoposide solution in NMP | |
| SE453497B (sv) | Antitumormedel och kompositioner pa basis derav samt forfarande for framstellning av dessa kompositioner | |
| JP4130700B2 (ja) | 抗腫瘍剤含有組成物 | |
| JPH0343251B2 (en, 2012) | ||
| KR102210848B1 (ko) | 3-포르밀리파마이신 sv 및 3-포르밀리파마이신 s의 3-(4-신나밀-1-피페라지닐) 아미노 유도체를 함유하는 제약 제제 및 그의 제조 방법 | |
| US3459854A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
| US3299124A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
| JPH032862B2 (en, 2012) | ||
| NO764182L (en, 2012) | ||
| US4575509A (en) | Water-soluble formulations of m-AMSA with pyroglutamic acid | |
| CA1159368A (en) | Antitumor compositions | |
| KR810002136B1 (ko) | 아목시실린 나트륨 함유 주사용 약제조성물의 제조방법 | |
| US4626541A (en) | Water soluble salt composition of m-AMSA | |
| JPH0315632B2 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8100341-0 Effective date: 19920806 Format of ref document f/p: F |